GAITHERSBURG, Md., Dec. 14, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company devoted to developing and commercializing next-generation vaccines for serious infectious diseases, today proclaimed a proposed underwritten public contribution to selling up to $125 million of its common stock.
In joining with the common stock offering, Novavax imagines granting to the underwriters a 30-day option to purchase up to an added $18.75 million of its common stock at the public offering price, less underwriting discounts, and directives.
Parallel with the offering of common stock, Novavax also broadcast an offering of $125 million aggregate major amount of convertible senior notes due 2027 (the “notes”) to persons reasonably supposed to be qualified institutional buyers under Instruction 144A under the Securities Act of 1933, as edited.
In connection with the notes offering, Novavax expects to grant the initial procurers a 30-day option to purchase up to an additional $18.75 million collective principal amount of the notes. The common stock offering is not contingent upon the consummation of the simultaneous offering of the notes, and the concurrent offering of the records is not contingent upon the consummation of the shared stock offering.
A registration declaration relating to the common stock offering was filed through the Securities and Exchange Commission (“SEC”) on March 11, 2020, and is actual. The common stock offering will be completed only using a prospectus supplement and the accompanying prospectus.
Read More: Shocking Calico Cooper’s Relieved His Net Worth Biography, Age, And Know Everything…
Before investing in the mutual stock offering, purchasers should read the preliminary list supplement relating to and describing the rapports of such a public offering and the related registration declaration and other documents Novavax has filed with the SEC for more comprehensive information about Noa vavax and such public offering. These papers!
when available, are free and can be found by going to EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and supplementary prospectus relating to the common stock offering may be obtained, when obtainable, from: J.P. Morgan, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by handset at (866) 803-9204 or by email at [email protected].
Jefferies LLC, Attention: Equity Association Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or thru email at [email protected] or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by phone at (833) 297-2926, or by email at [email protected].
Always be Updated with us visit GeeksULTD for Real-time Updates.
